FutureTech II Acquisition Corp. has entered into a merger agreement with Longevity Biomedical, Inc., where Longevity will become a wholly-owned subsidiary of FutureTech, with a merger consideration of approximately $100 million in shares, expected to close in Q4 2024 pending shareholder approvals.